|Bid||0.00 x 1300|
|Ask||0.00 x 100000|
|Day's Range||2,861.78 - 2,861.78|
|52 Week Range||2,500.00 - 3,590.00|
|PE Ratio (TTM)||271.83|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Pfizer, Inc. (PFE) announced that an FDA advisory committee has recommended approval of its biosimilar version of ESA Epogen and Procrit.
In 1Q17, Amgen’s (AMGN) Nplate generated revenues of ~$154 million, which reflected a year-over-year growth rate of 9%.
Harpoon Therapeutics Inc. has snared $45 million to develop a prostate cancer therapy that builds on the pioneering immuno-oncology research of co-founder Patrick Baeuerle.